BioXcel Therapeutics entered into the Thirteenth Amendment to its Credit Agreement and Guaranty on August 21, 2026. The amendment extends the deadline for entering definitive agreements regarding loan repayment or alternative capital solutions from August 21 to August 28, 2026. This transaction is material as it involves a critical covenant extension with lenders to avoid default under existing debt obligations. BioXcel Therapeutics operates in the biotechnology industry, focusing on the development of treatments for central nervous system disorders.
